The mechanism and significance of synergistic induction of the expression of plasminogen activator inhibitor-1 by glucocorticoid and transforming growth factor beta in human ovarian cancer cells

Molecular and Cellular Endocrinology

Volumn 407, Issue , 2015, Pages 37-45

  Pan, Xiao Yu ^a   Wang, Yan ^b   Su, Jie ^b   Huang, Gao Xiang ^b   Cao, Dong Mei ^b   Qu, Shen ^a   Lu, Jian ^b  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Dexamethasone; Ovarian cancer; Phosphorylation; Plasminogen activator inhibitor 1; Transforming growth factor beta

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; SERPINE1 PROTEIN, HUMAN; SMAD PROTEIN;

ARTICLE; CELL ADHESION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HO 8910 CELL LINE; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; AGONISTS; DRUG EFFECTS; DRUG POTENTIATION; EPITHELIUM CELL; FEMALE; GENETICS; METABOLISM; OVARY; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CELL ADHESION; CELL LINE, TUMOR; DEXAMETHASONE; DRUG SYNERGISM; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; OVARY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84925177557     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.03.005     Document Type: Article

References (58)

1. Almawi W.Y., Irani-Hakime N. The antiproliferative effect of glucocorticoids: is it related to induction of TGF-beta?. Nephrol. Dial. Transplant 1998, 13:2450-2452.
2. Anbalagan M., Huderson B., Murphy L., Rowan B.G. Post-translational modifications of nuclear receptors and human disease. Nucl. Recept. Signal 2012, 10:e001.
3. AyanlarBatuman O., Ferrero A.P., Diaz A., Jimenez S.A. Regulation of transforming growth factor-beta 1 gene expression by glucocorticoids in normal human T lymphocytes. J. Clin. Invest 1991, 88:1574-1580.
4. Baschant U., Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J. Steroid Biochem. Mol. Biol 2010, 120:69-75.
5. Beck I.M., Vanden Berghe W., Vermeulen L., Yamamoto K.R., Haegeman G., De Bosscher K. Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocr. Rev 2009, 30:830-882.
6. Beck L.S., DeGuzman L., Lee W.P., Xu Y., Siegel M.W., Amento E.P. One systemic administration of transforming growth factor-beta 1 reverses age- or glucocorticoid-impaired wound healing. J. Clin. Invest 1993, 92:2841-2849.
7. Bouazza B., Krytska K., Debba-Pavard M., Amrani Y., Honkanen R.E., Tran J., et al. Cytokines alter glucocorticoid receptor phosphorylation in airway cells: role of phosphatases. Am. J. Respir. Cell Mol. Biol 2012, 47:464-473.
8. Bruzdzinski C.J., Johnson M.R., Goble C.A., Winograd S.S., Gelehrter T.D. Mechanism of glucocorticoid induction of the rat plasminogen activator inhibitor-1 gene in HTC rat hepatoma cells: identification of cis-acting regulatory elements. Mol. Endocrinol 1993, 7:1169-1177.
9. Cai Z., Li Y.F., Liu F.Y., Feng Y.L., Hou J.H., Zhao M.Q. Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer. Ai Zheng 2007, 26:312-317.
10. Chen Y.X., Wang Y., Fu C.C., Diao F., Song L.N., Li Z.B., et al. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells. Endocr. Relat. Cancer 2010, 17:39-50.
11. Davies L., Karthikeyan N., Lynch J.T., Sial E.A., Gkourtsa A., Demonacos C., et al. Cross talk of signaling pathways in the regulation of the glucocorticoid receptor function. Mol. Endocrinol 2008, 22:1331-1344.
12. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998, 17:3091-3100.
13. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
14. Derynck R., Akhurst R.J., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet 2001, 29:117-129.
15. Durand M.K., Bodker J.S., Christensen A., Dupont D.M., Hansen M., Jensen J.K., et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb. Haemost 2004, 91:438-449.
16. Dziembowska M., Danilkiewicz M., Wesolowska A., Zupanska A., Chouaib S., Kaminska B. Cross-talk between Smad and p38 MAPK signalling in transforming growth factor beta signal transduction in human glioblastoma cells. Biochem. Biophys. Res. Commun 2007, 354:1101-1106.
17. Fang H., Placencio V.R., DeClerck Y.A. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J. Natl. Cancer Inst 2012, 104:1470-1484.
18. Galliher-Beckley A.J., Cidlowski J.A. Emerging roles of glucocorticoid receptor phosphorylation in modulating glucocorticoid hormone action in health and disease. IUBMB Life 2009, 61:979-986.
19. Ghosh A.K., Vaughan D.E. PAI-1 in tissue fibrosis. J. Cell. Physiol 2012, 227:493-507.
20. Gordon K.J., Blobe G.C. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim. Biophys. Acta 2008, 1782:197-228.
21. Halleux C.M., Declerck P.J., Tran S.L., Detry R., Brichard S.M. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J. Clin. Endocrinol. Metab 1999, 84:4097-4105.
22. Hamilton J.A., Whitty G.A., Wojta J., Gallichio M., McGrath K., Ianches G. Regulation of plasminogen activator inhibitor-1 levels in human monocytes. Cell. Immunol 1993, 152:7-17.
23. Housley P.R., Pratt W.B. Direct demonstration of glucocorticoid receptor phosphorylation by intact L-cells. J. Biol. Chem 1983, 258:4630-4635.
24. Kanatani Y., Kasukabe T., Okabe-Kado J., Hayashi S., Yamamoto-Yamaguchi Y., Motoyoshi K., et al. Transforming growth factor beta and dexamethasone cooperatively enhance c-jun gene expression and inhibit the growth of human monocytoid leukemia cells. Cell Growth Differ 1996, 7:187-196.
25. Kassel O., Herrlich P. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol. Cell. Endocrinol 2007, 275:13-29.
26. Kimura H., Li X., Torii K., Okada T., Kamiyama K., Mikami D., et al. Glucocorticoid enhances hypoxia- and/or transforming growth factor-beta-induced plasminogen activator inhibitor-1 production in human proximal renal tubular cells. Clin. Exp. Nephrol 2011, 15:34-40.
27. Kino T., Ichijo T., Amin N.D., Kesavapany S., Wang Y., Kim N., et al. Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol. Endocrinol 2007, 21:1552-1568.
28. Kobayashi T., Liu X., Wen F.Q., Kohyama T., Shen L., Wang X.Q., et al. Smad3 mediates TGF-beta1-induced collagen gel contraction by human lung fibroblasts. Biochem. Biophys. Res. Commun 2006, 339:290-295.
29. Koensgen D., Mustea A., Denkert C., Sun P.M., Lichtenegger W., Sehouli J. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. Anticancer Res 2006, 26:1683-1689.
30. Krstic M.D., Rogatsky I., Yamamoto K.R., Garabedian M.J. Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol. Cell. Biol 1997, 17:3947-3954.
31. Kwaan H.C., Mazar A.P., McMahon B.J. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin. Thromb. Hemost 2013, 39:382-391.
32. Li Z., Chen Y., Cao D., Wang Y., Chen G., Zhang S., et al. Glucocorticoid up-regulates transforming growth factor-beta (TGF-beta) type II receptor and enhances TGF-beta signaling in human prostate cancer PC-3 cells. Endocrinology 2006, 147:5259-5267.
33. Liu Y.X. Interaction and regulation of plasminogen activators and their inhibitor in rat follicles during periovulatory periods. Sci. Sin. [B.] 1988, 31:47-57.
34. Liu Y.X. Plasminogen activator/plasminogen activator inhibitors in ovarian physiology. Front. Biosci 2004, 9:3356-3373.
35. Lund L.R., Riccio A., Andreasen P.A., Nielsen L.S., Kristensen P., Laiho M., et al. Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J. 1987, 6:1281-1286.
36. Ma Y., Ryu J.S., Dulay A., Segal M., Guller S. Regulation of plasminogen activator inhibitor (PAI)-1 expression in a human trophoblast cell line by glucocorticoid (GC) and transforming growth factor (TGF)-beta. Placenta 2002, 23:727-734.
37. Massague J. TGFbeta in cancer. Cell 2008, 134:215-230.
38. Miller A.L., Webb M.S., Copik A.J., Wang Y., Johnson B.H., Kumar R., et al. p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol. Endocrinol 2005, 19:1569-1583.
39. Miller A.L., Garza A.S., Johnson B.H., Thompson E.B. Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells. Cancer Cell Int 2007, 7:3.
40. Mou H.Z., Xu S.H., Zhang Y.Y. The establishment of human ovarian carcinoma cell line HO-8910 and its characteristics. Zhonghua Fu Chan Ke Za Zhi 1994, 29:162-164. 191.
41. Ny T., Bjersing L., Hsueh A.J., Loskutoff D.J. Cultured granulosa cells produce two plasminogen activators and an antiactivator, each regulated differently by gonadotropins. Endocrinology 1985, 116:1666-1668.
42. Ohshima T., Shimotohno K. Transforming growth factor-beta-mediated signaling via the p38 MAP kinase pathway activates Smad-dependent transcription through SUMO-1 modification of Smad4. J. Biol. Chem 2003, 278:50833-50842.
43. Oursler M.J., Riggs B.L., Spelsberg T.C. Glucocorticoid-induced activation of latent transforming growth factor-beta by normal human osteoblast-like cells. Endocrinology 1993, 133:2187-2196.
44. Peltier J., Perez J., Bellocq A., Escoubet B., Fouqueray B., Baud L. Transforming growth factor-beta 1 increases glucocorticoid binding and signaling in macrophages through a Smad- and activated protein-1-mediated process. Kidney Int 2003, 63:2028-2036.
45. Peng C. The TGF-beta superfamily and its roles in the human ovary and placenta. J. Obstet. Gynaecol. Can 2003, 25:834-844.
46. Periyasamy S., Sanchez E.R. Antagonism of glucocorticoid receptor transactivity and cell growth inhibition by transforming growth factor-beta through AP-1-mediated transcriptional repression. Int. J. Biochem. Cell Biol 2002, 34:1571-1585.
47. Phuc Le P., Friedman J.R., Schug J., Brestelli J.E., Parker J.B., Bochkis I.M., et al. Glucocorticoid receptor-dependent gene regulatory networks. PLoS Genet 2005, 1. e16.
48. Pierce G.F., Mustoe T.A., Lingelbach J., Masakowski V.R., Gramates P., Deuel T.F. Transforming growth factor beta reverses the glucocorticoid-induced wound-healing deficit in rats: possible regulation in macrophages by platelet-derived growth factor. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:2229-2233.
49. Rae M.T., Niven D., Ross A., Forster T., Lathe R., Critchley H.O., et al. Steroid signalling in human ovarian surface epithelial cells: the response to interleukin-1alpha determined by microarray analysis. J. Endocrinol 2004, 183:19-28.
50. Rerolle J.P., Hertig A., Nguyen G., Sraer J.D., Rondeau E.P. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000, 58:1841-1850.
51. Sheen Y.Y., Kim M.J., Park S.A., Park S.Y., Nam J.S. Targeting the transforming growth factor-beta signaling in cancer therapy. Biomol. Ther. (Seoul) 2013, 21:323-331.
52. Song C.Z., Tian X., Gelehrter T.D. Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad3. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:11776-11781.
53. Takuma A., Kaneda T., Sato T., Ninomiya S., Kumegawa M., Hakeda Y. Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J. Biol. Chem 2003, 278:44667-44674.
54. Vasilaki E., Papadimitriou E., Tajadura V., Ridley A.J., Stournaras C., Kardassis D. Transcriptional regulation of the small GTPase RhoB gene by TGF{beta}-induced signaling pathways. FASEB J. 2010, 24:891-905.
55. Wang Z., Chen W., Kono E., Dang T., Garabedian M.J. Modulation of glucocorticoid receptor phosphorylation and transcriptional activity by a C-terminal-associated protein phosphatase. Mol. Endocrinol 2007, 21:625-634.
56. Wickert L., Chatain N., Kruschinsky K., Gressner A.M. Glucocorticoids activate TGF-beta induced PAI-1 and CTGF expression in rat hepatocytes. Comp. Hepatol 2007, 6:5.
57. Zhang Y.E. Non-Smad pathways in TGF-beta signaling. Cell Res 2009, 19:128-139.
58. Zorio E., Gilabert-Estelles J., Espana F., Ramon L.A., Cosin R., Estelles A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr. Med. Chem 2008, 15:923-929.